The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA ® (zanubrutinib) ...

Wu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic ...

Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX) ...

EEST HELSINKI, FINLAND, June 12, 2025 - Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had started ...

To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of ...

Luton, Bedfordshire, United Kingdom, June 13, 2025 (GLOBE NEWSWIRE) -- The global cellulose market is poised for steady and significant growth over the next decade, with a valuation expected to rise ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

The global Binder Excipients market, valued at US$2.0 Billion in 2024, is set to reach US$2.7 Billion by 2030 with a CAGR of 5.3%. Key drivers includ ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...